Kidney function and the effectiveness and safety Of DIrect oral AntiCoagulant therapy in Atrial Fibrillation: a metaanalysis of population-based cohort studies KODIAC-AF study

Project number: 
19-126
Approval date: 
Wednesday, March 25, 2020
Principal Investigator: 
Birks,Peter
Institution: 
BC Provincial Renal Agency (BCPRA)
Funding Agency: 
National Health and Medical Research Council. Australian Government
Datasets requested: 
Deaths (BC Vital Statistics Agency)
Hospital Separations (BC Ministry of Health)
consolidation - census geocodes
NACRS
Medical Services Plan (BC Ministry of Health)
Consolidation file (BC Ministry of Health)
PharmaNet
Consolidation - demographic (Ministry of Health)
Research objective: 

Objectives:
1) To investigate patterns of DOAC use (overall and by agent [defined as dabigatran, rivaroxaban and apixaban]) according to levels of kidney function in adults with AF.

2) To investigate whether the association between DOAC therapy (compared with warfarin) and the risk of ischaemic stroke, transient ischaemic attack (TIA) or death (effectiveness) is modified by kidney function in adults with AF.

3) To investigate whether the association between DOAC therapy (compared with warfarin) and the risk of major bleeding (safety) is modified by kidney function in adults with AF.

Hypothesis:
Patient with lower levels of kidney function (below GFR 30 mL/min/1,73m^2) will not have the same lower risk-benefit of taking DOACs as compared to warfarin.


Page last revised: May 5, 2020